Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL30899743 | 1.00 | TSHR (0.50) | TSHRTHRBMEN1KMT2ANFKB1 | |
| Cadaverine Tartrate SCHEMBL17439178 | 1.00 | TSHR (0.50) | TSHRTHRBMEN1KMT2ANFKB1 | |
| Tartaric Acid SCHEMBL30276688 | 1.00 | TSHR (0.50) | TSHRTHRBMEN1KMT2ANFKB1 | |
| Cadaverine Tartrate SCHEMBL5804440 | 1.00 | TSHR (0.50) | TSHRTHRBMEN1KMT2ANFKB1 | |
| Cadaverine Tartrate SCHEMBL918361 | 1.00 | TSHR (0.50) | TSHRTHRBMEN1KMT2ANFKB1 | |
| Cadaverine Tartrate SCHEMBL30899742 | 1.00 | TSHR (0.50) | TSHRTHRBMEN1KMT2ANFKB1 | |
| Cadaverine Tartrate SCHEMBL2998062 | 0.83 | TSHR (0.48) | TSHRNFKB1CYP2C19MMP2MMP1 | |
| SCHEMBL11367816 | 0.83 | THRB (0.48) | THRBMEN1KMT2AMMP2MMP9 | |
| Cadaverine Tartrate SCHEMBL30432913 | 0.81 | THRB (0.46) | TSHRTHRBMEN1KMT2AMMP2 | |
| SCHEMBL8939281 | 0.81 | THRB (0.46) | THRBMEN1KMT2AMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116333294-B | Catalyst for preparing block polyether and preparation method of block polyether | 辽宁奥克药业股份有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-116333294-A | Catalyst for preparing block polyether and preparation method of block polyether | 辽宁奥克药业股份有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-112675576-A | Oil-water separation membrane and preparation method and application thereof | 天津大学 | 2021-04-20 | — | — | CN | claimed |
| CN-116333294-B | Catalyst for preparing block polyether and preparation method of block polyether | 辽宁奥克药业股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-116333294-A | Catalyst for preparing block polyether and preparation method of block polyether | 辽宁奥克药业股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-112675576-B | Oil-water separation membrane and preparation method and application thereof | 天津大学 | 2022-05-31 | — | — | CN | disclosed |
| CN-108940369-B | Preparation method and application of salen Cu (II) catalyst | 湖南亚王医药科技有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-112675576-A | Oil-water separation membrane and preparation method and application thereof | 天津大学 | 2021-04-20 | — | — | CN | disclosed |
| EP-2977368-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE TRANS-1,2-DIAMINOCYCLOHEXANE | TORAY FINECHEMICALS CO LTD (JP) | 2019-06-12 | — | — | EP | disclosed |
| CN-108940369-A | A kind of preparation method and applications of salen Cu (II) catalyst | 湖南亚王医药科技有限公司 | 2018-12-07 | — | — | CN | disclosed |
| CN-104710447-B | A kind of preparation method of chiral aluminum complex containing pyrrole group and preparation method thereof and PLA | 长春理工大学 | 2017-06-20 | — | — | CN | disclosed |
| CN-100482671-C | Chiral monophosphorous ligand, synthetic method and its use | SHANGHAI INST ORGANIC CHEM (CN) | 2009-04-29 | — | — | CN | disclosed |
| EP-2011798-A1 | Preparation of platinum (II) complexes | Platco Technologies (Proprietary) Limited (ZA) | 2009-01-07 | — | — | EP | disclosed |
| US-20080064895-A1 | Preparation of Platinum(II) Complexes | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2008-03-13 | — | — | US | disclosed |
| CN-1616470-A | Chiral monophosphorous ligand, synthetic method and its use | SHANGHAI INST ORGANIC CHEM (CN) | 2005-05-18 | — | — | CN | disclosed |
| US-6486347-B2 | REACTING DIARYLPHOSPHINOBENZOIC ACID WITH AN AMINE | CHIROTECH TECHNOLOGY, LTD. (GB) | 2002-11-26 | — | — | US | disclosed |
| US-20010011145-A1 | Preparation of phosphine ligands | LENNON IAN CAMPBELL (GB) | 2001-08-02 | — | — | US | disclosed |
| WO-2001022915-A2 | PROCESS FOR PRODUCTION OF CIS-DICHLORO-(TRANS-1-1,2-CYCLOHEXANEDIAMINE)PLATINUM(II) | PLIVA-LACHEMA A.S. (CZ) | 2001-04-05 | — | — | WO | disclosed |
| US-5420319-A | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same | TANAKA KIKINZOKU KOGYO K.K. (JP) | 1995-05-30 | — | — | US | disclosed |
| EP-0625523-A1 | Cis-oxalato(trans-L-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same | Tanaka Kikinzoku Kogyo K.K. (JP) | 1994-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064895-A1 | Preparation of Platinum(II) Complexes | SLCO4C1, SLC10A6, OTC | TSHR 3144/4885THRB 4590/4885MEN1 1588/4885 |
| US-20010011145-A1 | Preparation of phosphine ligands | PTGER4, PTGER3, P2RX3 | TSHR 406/4885THRB 2219/4885MEN1 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.